A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection  

作　　者：Valerio F.Annese Samadhan B.Patil Chunxiao Hu Christos Giagkoulovits Mohammed A.Al-Rawhani James Grant Martin Macleod David J.Clayton Liam M.Heaney Ronan Daly Claudio Accarino Yash D.Shah Boon C.Cheah James Beeley Thomas R.Jeffry Evans Robert Jones Michael P.Barrett David R.S.Cumming 

机构地区：[1]Electronics and Nanoscale Engineering,James Watt School of Engineering,University of Glasgow,Glasgow,G128QQ,UK [2]Beatson West of Scotland Cancer Centre,Glasgow,G120YN,UK [3]School of Science and Technology,Nottingham Trent University,Nottingham,NG118NF,UK [4]School of Sport,Exercise&Health Sciences,Loughborough University,Loughborough,LE113TU,UK [5]Glasgow Polyomics,College of Medical,Veterinary and Life Sciences,University of Glasgow,Glasgow,G611BD,UK [6]Institute of Cancer Sciences,Beatson West of Scotland Cancer Centre,University of Glasgow,Glasgow,G120YN,UK [7]Institute of Infection,Immunity and Inflammation,University of Glasgow,Glasgow,G128TA,UK

出　　处：《Microsystems & Nanoengineering》2021年第2期81-95,共15页微系统与纳米工程（英文）

基　　金：This work was supported by EPSRC grants EP/K021966/1 and EP/L023652/1.S.B.P.is now at the Department of Electronic Engineering&York Biomedical Research Institute,University of York,York,YO105DD UK.M.P.B.is part of the Wellcome Centre for Integrative Parasitology funded by a Wellcome Trust core grant(104111/Z/14/Z).

摘　　要：There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor’s office to reduce the impact of serious disease.Many cancers are diagnosed late,leading to costly treatment and reduced life expectancy.With prostate cancer,the absence of a reliable test has inhibited the adoption of screening programs.We report a microelectronic point-of-care metabolite biomarker measurement platform and use it for prostate cancer detection.The platform,using an array of photodetectors configured to operate with targeted,multiplexed,colorimetric assays confined in monolithically integrated passive microfluidic channels,completes a combined assay of 4 metabolites in a drop of human plasma in under 2 min.A preliminary clinical study using L-amino acids,glutamate,choline,and sarcosine was used to train a cross-validated random forest algorithm.The system demonstrated sensitivity to prostate cancer of 94%with a specificity of 70%and an area under the curve of 0.78.The technology can implement many similar assay panels and hence has the potential to revolutionize low-cost,rapid,point-of-care testing.

关 键 词：inhibited SPECIFICITY hence 

分 类 号：R737.25[医药卫生—肿瘤]